Table of Contents
Table of Contents
1 Table Of Contents 2
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 17
2.1 What Is This Report
About? 17
2.2 Definitions 17
2.2.1 Diabetes Care Devices 17
2.2.1.1 Glucose Monitoring 17
2.2.1.2 Insulin Delivery 17
3 Healthcare
Sector Review 19
3.1 Healthcare Expenditure 19
3.2 Healthcare
Infrastructure 24
3.2.1 Healthcare Personnel Data 26
3.2.2 Healthcare
Facilities Data 29
4 Diabetes Care Devices in United States 31
4.1
Diabetes Care Devices Overall Revenues (2000-2012) 31
4.2 Diabetes Care
Devices Overall Volume (2000-2012) 37
4.3 Diabetes Care Devices Overall
Company Share (2005-2006) 40
5 Glucose Monitoring in United States 41
5.1 Glucose Monitoring Overall Revenues (2000-2012) 41
5.1.1 Blood Glucose
Test Strips Overall Revenues (2000-2012) 45
5.1.2 Blood Glucose Meters
Overall Revenues (2000-2012) 46
5.2 Glucose Monitoring Overall Volume
(2000-2012) 49
5.2.1 Blood Glucose Test Strips Overall Volumes (2000-2012)
49
5.2.2 Blood Glucose Meters Overall Volumes (2000-2012) 51
5.3
Glucose Monitoring Average Price (2000-2012) 54
5.3.1 Blood Glucose Meters
Average Price (2000-2012) 54
5.3.2 Blood Glucose Test Strips Average Price
(2000-2012) 56
5.4 Glucose Monitoring Distribution Share (2005-2006)
58
5.5 Glucose Monitoring Company Share (2005-2006) 59
6 Insulin
Delivery in United States 60
6.1 Insulin Delivery Overall Revenues
(2000-2012) 60
6.1.1 Insulin Syringes Overall Revenues (2000-2012) 64
6.1.2 Insulin Pumps Overall Revenues (2000-2012) 66
6.1.3 Insulin Pens
Overall Revenues (2000-2012) 68
6.1.4 Insulin Jet Injectors Overall
Revenues (2000-2012) 70
6.2 Insulin Delivery Overall Volume (2000-2012)
72
6.2.1 Insulin Syringes Overall Volume (2000-2012) 72
6.2.2 Insulin
Pumps Overall Volume (2000-2012) 75
6.2.3 Insulin Pens Overall Volume
(2000-2012) 77
6.2.4 Insulin Jet Injectors Overall Volume (2000-2012)
79
6.3 Insulin Delivery Average Price (2000-2012) 81
6.3.1 Insulin Jet
Injectors Average Price (2000-2012) 81
6.3.2 Insulin Pens Average Price
(2000-2012) 82
6.3.3 Insulin Pumps Average Price (2000-2012) 85
6.3.4
Insulin Syringes Average Price (2000-2012) 87
6.4 Insulin Delivery
Distribution Share (2005-2006) 89
6.5 Insulin Delivery Company Share
(2005-2006) 90
7 F. Hoffmann-La Roche Ltd. Company Profile 91
7.1
Company Overview 91
7.2 Business Overview 91
7.2.1 Diagnostics 91
7.2.2 Pharmaceuticals 92
7.2.3 History 92
7.3 Value Chain Analysis
95
7.3.1 Manufacturing 95
7.3.2 Product Development 96
7.3.3 Sales
and Marketing 97
7.4 SWOT Analysis 97
7.4.1 F. Hoffmann-La Roche Ltd.
Strengths 98
7.4.2 F. Hoffmann-La Roche Ltd. Weaknesses 99
7.4.3 F.
Hoffmann-La Roche Ltd. Opportunities 99
7.4.4 F. Hoffmann-La Roche Ltd.
Threats 100
7.5 Financial and Operational Review 101
7.5.1 Financial
Statements 101
7.5.2 Financial Ratios 102
7.6 Locations And
Subsidiaries 103
7.7 Financial Deals Landscape 105
7.7.1 Roche
Acquires Ventana Medical Systems 105
7.7.2 Roche Signs An Agreement With
ACEA Biosciences 107
7.7.3 Roche Signs Licensing Agreement With
Ortho-Clinical Diagnostics And Novartis Vaccines & Diagnostics 108
7.7.4
Roche Acquires Nimblegen 110
7.7.5 Roche Signs An Agreement With Ipsen
112
7.7.6 Roche Signs Licensing Agreement With Alnylam Pharmaceuticals
113
7.7.7 Roche acquires BioVeris 115
7.7.8 Roche Signs An Agreement
With Toyama Chemical 117
7.7.9 Roche Acquires 454 Life Sciences 118
7.7.10 Roche And Transgene Enter Into A Partnership Agreement 120
7.7.11
Roche Acquires Therapeutic Human Polyclonals 122
7.7.12 Proacta, Inc.
completes $35 million series B financing 123
7.7.13 Roche Diagnostics
Signs An Agreement With Multilyte 125
7.7.14 Roche Diagnostics Signs An
Agreement With ThromboGenics And Geymonat 127
7.7.15 Roche Signs An
Agreement With InterMune 129
7.7.16 Roche Signs An Agreement With BioCryst
Pharmaceuticals 131
7.7.17 Roche Signs An Agreement With PDL BioPharma
132
7.7.18 Innogenetics Signs An Agreement With Roche Diagnostics 134
7.7.19 Roche Diagnostics Signs An Agreement With Response Biomedical 136
7.7.20 Roche Acquires GLYCART biotechnology 137
7.7.21 Roche Diagnostics
Signs An Agreement With Amplimedical 139
7.7.22 Roche Diagnostics Signs An
Agreement With Exiqon 140
7.7.23 Roche Signs An Agreement With 454 Life
Sciences 142
7.7.24 Roche Diagnostics Signs An Agreement With bioMerieux
144
7.7.25 Roche Sells Roche Consumer Health To Bayer HealthCare 145
7.7.26 Roche Signs An Agreement With deCODE genetics 147
7.7.27 Roche
Signs An Agreement With PDL BioPharma 148
7.7.28 Roche Signs An Agreement
With Japan Tobacco 150
7.7.29 Roche Diagnostics Signs An Agreement With
Institut Pasteur And Bio-Rad Laboratories 151
7.7.30 Roche Diagnostics
Signs An Agreement With Ortho-Clinical Diagnostics 153
7.7.31 Roche
Diagnostics Signs An Agreement With Inverness Medical 155
7.7.32 Roche To
Sell Three Pharmaceutical Products To Actavis 156
7.8 Recent Developments
158
7.8.1 Mar 04, 2008: Roche raises dividend by 35 percent 158
7.8.2
Jan 30, 2008: Roche Reports 2007 Results 159
7.8.3 Oct 23, 2007: Roche
Considers Legal Options In Patent Litigation Case 160
7.8.4 Oct 16, 2007:
Roche Declares First Nine Months 2007 Results 160
7.8.5 Oct 02, 2007:
Roche Names New CEO For Diagnostics Division 162
7.8.6 Jul 19, 2007: Roche
Reports H1 2007 Results 162
7.8.7 May 30, 2007: NorDiag Enters
Distribution Agreement With Roche 164
7.8.8 Apr 18, 2007: Roche Reports Q1
2007 Results 164
7.8.9 Feb 07, 2007: Roche Reports Full-Year 2006 Results
166
7.8.10 Oct 17, 2006: Roche Reports Nine-Months Ended 2006 Results
168
8 LifeScan, Inc. Company Profile 171
8.1 Company Overview 171
8.2 Business Overview 171
8.2.1 Major Products and Services 172
8.2.2
History 172
8.3 Locations And Subsidiaries 172
8.4 Recent Developments
174
8.4.1 Oct 30, 2007: LifeScan, UBS Enter Agreement 174
8.5
LifeScan, Inc. Pipeline Products 174
8.5.1 Blood Glucose Test 174
8.5.1.1 Product Overview 174
8.5.1.2 Product Description 174
8.5.1.3
Product Status 174
8.5.2 OneTouch glucose meter 174
8.5.2.1 Product
Overview 174
8.5.2.2 Product Description 174
8.5.2.3 Product Status
175
8.5.2.4 Product Milestone 175
9 Abbott Laboratories Company
Profile 177
9.1 Company Overview 177
9.2 Business Overview 177
9.2.1 Diagnostics 177
9.2.2 Nutritionals 177
9.2.3 Pharmaceuticals
178
9.2.4 Vascular 178
9.2.5 Major Products and Services 179
9.2.6
History 180
9.3 Value Chain Analysis 182
9.3.1 Manufacturing 182
9.3.2 Product Development 182
9.3.3 Sales and Marketing 184
9.4 SWOT
Analysis 184
9.4.1 Abbott Laboratories Strengths 184
9.4.2 Abbott
Laboratories Weaknesses 185
9.4.3 Abbott Laboratories Opportunities
186
9.4.4 Abbott Laboratories Threats 186
9.5 Financial and
Operational Review 188
9.5.1 Financial Statements 188
9.5.2 Financial
Ratios 189
9.5.3 Share Holding Structure 190
9.6 Locations And
Subsidiaries 190
9.7 Financial Deals Landscape 192
9.7.1 Luminex
Enters Into A Partnership Agreement With Abbott 192
9.7.2 Evalve Secures
$60 Million In Series D Financing 193
9.7.3 Abbott Acquires Kos
Pharmaceuticals 195
9.7.4 Abbott Laboratories Enters Into An Agreement
With Enanta Pharmaceuticals 196
9.7.5 Abbott Laboratories Enters Into
Distribution Agreement With Verax 198
9.7.6 AstraZeneca Signs An Agreement
With Abbott 199
9.7.7 Abbott Laboratories Enters Into Licensing Agreement
With Advanced Life Science 201
9.7.8 Abbott Acquires Vascular Business Of
Guidant From Boston Scientific 202
9.7.9 Abbott Enters Into An Agreement
With Axis-Shield 204
9.7.10 Abbott Enters Into Licensing Agreement With
Nephromics 206
9.7.11 Abbott Enters Into Licensing Agreement With BioCurex
207
9.7.12 Nihon Kohden And Abbott Laboratories Enter Into
Commercialization Agreement 208
9.7.13 Abbott Signs An Agreement With
OraSure 210
9.7.14 Abbott Enters Into Licensing Agreement With Cleveland
Clinic 211
9.7.15 Chattem Acquires Selsun Blue 213
9.7.16 Abbott
Terminates The Deal To Divest Its Divisions To GE Healthcare 214
9.7.17 GE
Healthcare terminates the acquisition of In vitro diagnostics and
Point-of-Care diagnostics businesses of Abbott 216
9.8 Recent Developments
218
9.8.1 Apr 01, 2008: Abbott To Declare Q1 2008 Results 218
9.8.2
Jan 23, 2008: Abbott Declares Q4 2007 Results 218
9.8.3 Jan 03, 2008:
Abbott To Declare Q4 And Year-End 2007 Results 219
9.8.4 Dec 14, 2007:
Abbott Declares Quarterly Dividend 219
9.8.5 Oct 17, 2007: Abbott Declares
Q3 2007 Results 219
9.8.6 Aug 03, 2007: Abbott COO To Retire 220
9.8.7
Jul 18, 2007: Abbott Reports Q2 2007 Results 220
9.8.8 Jul 11, 2007:
Abbott Announces Termination Of Contract With GE 221
9.8.9 Jun 14, 2007:
Abbott Declares Quarterly Dividend 221
9.8.10 Apr 18, 2007: Abbott
Declares Quarterly Dividend 221
9.8.11 Apr 18, 2007: Abbott Reports Q1
2007 Results 221
9.8.12 Apr 10, 2007: Abbott Opens New Biotechnology
Manufacturing Unit in Puerto Rico 222
9.8.13 Jan 24, 2007: Abbott Declares
Quarterly Dividend 223
9.8.14 Jan 24, 2007: Abbott Reports Q4 2006 Results
223
9.8.15 Jan 08, 2007: Abbott m2000・ Instrument and Viral Load Tests for
HIV-1 and HCV Approved in Canada 224
9.8.16 226
9.8.17 Dec 20, 2006:
Abbott To Voluntarily Delist From NYSE Arca 226
9.8.18 Oct 18, 2006:
Abbott Announces Share Repurchase Program 226
9.8.19 Oct 18, 2006: Abbott
Declares Quarterly Dividend 227
9.8.20 Oct 18, 2006: Abbott Reports Q3
2006 Results 227
9.8.21 Jul 19, 2006: Abbott Declares Quarterly Dividend
227
9.8.22 Jul 19, 2006: Abbott Reports Q2 2006 Results 228
9.8.23 Apr
19, 2006: Abbott Declares Quarterly Dividend 228
9.8.24 Apr 19, 2006:
Abbott Reports Q1 2006 Results 228
9.8.25 Jan 20, 2006: Abbott Names New
Director To The Board 229
9.9 Abbott Laboratories Pipeline Products
229
9.9.1 Fully Biosorbable Stent 229
9.9.1.1 Product Overview 229
9.9.1.2 Product Description 229
9.9.1.3 Product Status 229
9.9.1.4
Product Milestone 231
9.9.2 FreeStyle Navigator Continuous Glucose
Monitoring System 232
9.9.2.1 Product Overview 232
9.9.2.2 Product
Description 232
9.9.2.3 Product Status 233
9.9.2.4 Product Milestone
234
9.9.3 Wallis System 234
9.9.3.1 Product Overview 234
9.9.3.2
Product Description 234
9.9.3.3 Product Status 235
9.9.3.4 Product
Milestone 236
10 Novo Nordisk A/S Company Profile 237
10.1 Company
Overview 237
10.2 Business Overview 237
10.2.1 Major Products and
Services 237
10.2.2 History 238
10.3 Locations And Subsidiaries
238
10.4 Recent Developments 241
10.4.1 Feb 25, 2008: Novo Nordisk AS
- Share repurchase programme 241
10.4.2 Feb 20, 2008: Annual General
Meeting of Novo Nordisk AS 241
10.4.3 Feb 18, 2008: Novo Nordisk AS -
Share repurchase programme 241
10.4.4 Feb 13, 2008: Trading in Novo
Nordisk shares by board members, executives and associated persons as reported
to Novo Nordisk on 12 February 2008 242
10.4.5 Jan 31, 2008: Novo Reports
2007 Results 242
10.4.6 Oct 31, 2007: Novo Declares Nine Months Ended 2007
Results 244
10.4.7 Aug 03, 2007: Novo Reports H1 2007 Results 245
10.4.8 May 02, 2007: Novo Reports Q1 2007 Results 246
10.4.9 Jan 31, 2007:
Novo Reports 2006 Results 247
10.5 Novo Nordisk A/S Pipeline Products
248
10.5.1 Future inhalation systems 248
10.5.1.1 Product Overview
248
10.5.1.2 Product Description 248
10.5.1.3 Product Status 248
10.5.2 Future insulin infusion systems 248
10.5.2.1 Product Overview
248
10.5.2.2 Product Description 248
10.5.2.3 Product Status 248
10.5.3 Next generation durable pen 248
10.5.3.1 Product Overview 248
10.5.3.2 Product Description 248
10.5.3.3 Product Status 249
10.5.4
Next generation needles 249
10.5.4.1 Product Overview 249
10.5.4.2
Product Description 249
10.5.4.3 Product Status 249
11 Becton,
Dickinson Company Profile 250
11.1 Company Overview 250
11.2 Business
Overview 250
11.2.1 Biosciences 250
11.2.2 Diagnostics 250
11.2.3
Medical 251
11.2.4 Major Products and Services 252
11.2.5 History
252
11.3 Value Chain Analysis 254
11.3.1 Manufacturing 254
11.3.2
Product Development 254
11.3.3 Sales and Marketing 255
11.4 SWOT
Analysis 255
11.4.1 Becton, Dickinson and Company Strengths 256
11.4.2
Becton, Dickinson and Company Weaknesses 256
11.4.3 Becton, Dickinson and
Company Opportunities 257
11.4.4 Becton, Dickinson and Company Threats
258
11.5 Financial and Operational Review 259
11.5.1 Financial
Statements 259
11.5.2 Financial Ratios 260
11.5.3 Share Holding
Structure 261
11.6 Locations And Subsidiaries 261
11.7 Financial Deals
Landscape 263
11.7.1 Becton, Dickinson And Company Acquires Tripath
Imaging 263
11.7.2 Becton, Dickinson Acquires Geneohm Sciences 264
11.7.3 Becton, Dickinson And Company Sells Clontech To Takara Bio 266
11.7.4 Becton, Dickinson and Company Acquires Protein Separation Technology
from FFE Weber 267
11.7.5 Becton, Dickinson and Company Acquires Atto
Bioscience 269
11.7.6 Argos Therapeutics Secures $39.5 Million In Series B
Financing 270
11.8 Recent Developments 281
11.8.1 Mar 18, 2008: BD
Board of Directors Elects John R. Considine as Vice Chairman and Member of the
Board of Directors 281
11.8.2 Mar 18, 2008: BD Elects New Vice Chairman,
CFO 281
11.8.3 Mar 18, 2008: BD Elects Vice Chairman And Board Member
281
11.8.4 Mar 14, 2008: BD Expands Operations In US 281
11.8.5 Jan
29, 2008: BD Declares Quarterly Dividend 282
11.8.6 Jan 24, 2008: BD
Reports Q1 Fiscal 2008 Results 282
11.8.7 Nov 20, 2007: BD Declares
Quarterly Dividend 283
11.8.8 Nov 02, 2007: BD Elects New Board Member
283
11.8.9 Nov 01, 2007: BD Reports Q4 Fiscal 2007 Results 284
11.8.10
Jul 26, 2007: BD Reports Q3 Fiscal 2007 Results 285
11.8.11 Jul 24, 2007:
BD Announces Share Repurchase Program 286
11.8.12 Jul 24, 2007: BD
Declares Quarterly Dividend 286
11.8.13 Jul 24, 2007: BD Elects New
Director 286
11.8.14 May 22, 2007: BD Declares Quarterly Dividend 286
11.8.15 Apr 25, 2007: BD Reports Q2 Fiscal 2007 Results 286
11.8.16 Jan
30, 2007: BD Declares Quarterly Dividend 288
11.8.17 Jan 25, 2007: BD
Reports Q1 Fiscal 2007 Results 288
12 Regulation System 290
12.1
Regulation System 290
12.2 Medical Equipment Approval Process 290
12.2.1 Pre-market Approval Process 291
12.2.2 Intended use and Indications
for use 291
12.2.3 Predicate Device 291
12.2.4 Safe and Effective
292
12.2.5 Other Category Devices 294
12.2.6 Post-Market Approval
Process 295
12.2.7 Compliance and Enforcement 295
12.2.8 Registration
Fee 295
12.2.9 Approval Time 296
13 Pricing and Reimbursement 297
13.1 Government Policies 297
13.2 Private Insurance 298
13.3 Diagnosis
Related Groups (DRG) 299
14 Distribution Structure 300
14.1
Distribution Structure 300
15 APPENDIX 301
15.1 Global Markets Direct
Research Methodology 301
15.2 Coverage 302
15.3 Secondary Research
302
15.4 Primary Research 303
15.5 Models 303
15.6 Forecasts
304
15.7 Expert Panels 304
15.8 Currency Conversion 305
15.9
Contact Us 306
15.10 Disclaimer 306
View Cart
